Drug name - Jevtana Kit
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7241907 | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Dec, 2025
(3 years from now) | |
| CN100429207C | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| CN1849311A | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Compound And Preparation Method Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| IN253669B | SANOFI AVENTIS US | A Process For The Preparation Of Acetone Solvate Of Dimethoxy Docetaxel |
Sep, 2024
(1 year, 11 months from now) | |
| IN200600944P4 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Sep, 2024
(1 year, 11 months from now) | |
| EP1667986A1 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Mar, 2026
(3 years from now) | |
| EP1667986B1 | SANOFI AVENTIS US | Dimethoxy Docetaxel Acetone Solvate Et Method For The Preparation Thereof |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7241907
(Pediatric) | SANOFI AVENTIS US | Acetone solvate of dimethoxy docetaxel and its process of preparation |
Jun, 2026
(3 years from now) | |
| US10583110 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
| US10716777 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(8 years from now) | |
|
US8927592
(Pediatric) | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Apr, 2031
(8 years from now) | |
Drugs and Companies using CABAZITAXEL ingredient
Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 60MG/1.5ML (40MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.